Erratum

Errata

This article corrects:

  1. Bioequivalence of a new liquid formulation of benazepril compared with the reference tablet product Volume 91, Issue 8, 312–319, Article first published online: 26 July 2013

Aust Vet J 2013;91:312–319. DOI: 10.1111/avj.12080

Bioequivalence of a new liquid formulation of benazepril compared with the reference tablet product

K Kelers, JL Devi, GA Anderson, P Zahra, JH Vine and T Whittem

The editors wish to correct the following typographical errors in this article:

1. The analytical procedures section of the Materials and methods, lines 10–15 of the second paragraph, should read:

The dried extract was reconstituted in mobile phase (1% acetic acid: methanol, 95:5 v/v, 200 μL) for liquid chromatography mass spectrometry analysis performed on a Quantum Access triple quadrupole mass spectrometer (Thermo Fisher) coupled to a 1200 series binary pump (Agilent Technologies).

2. Lines 5–7 of the third paragraph of the Analytical procedures section should read:

Transitions (relative collision energy) of 1 ms2 for each analyte were chosen and used for quantitation as follows: benazepril m/z 425.1→351.0 (20%), benazepril-d5 m/z 430.1 → 356.0 (20%), benazeprilat m/z 397.1 → 351.0 (18%) and benazeprilat-d5 m/z 402.1 → 356.0 (18%).

3. Table 1 was unfortunately laid out incorrectly in the original article. The correct version is as follows:

Table 1. Sample population values for estimates of benazepril pharmacokinetic variables: group A and group B day-7 AUC values from dosing to 10 h post-dosing for angiotensin-converting enzyme (ACE) and from dosing to 24 h post-dosing for both benazepril and benazeprilat for group A (liquid) and group B (tablet)a
 ACEBenazeprilatBenazepril
AUC(0–10) (%inhibition.h)AUC (h.µg/L)Cmax (μg/L)AUC (h.µg/L)AUMC (h2.µg/L)Cl/F (L/h/kg)MRT (h)
  1. aDogs in group A were dosed daily for 8 days with a mean dose of 0.451 mg/kg benazepril as the tablet formulation for days 0–3 followed by the liquid formulation for days 4–7. Dogs in group B were dosed daily for 8 days with a mean dose of 0.451 mg/kg benazepril as the liquid formulation for days 0–3 followed by the tablet formulation for days 4–7.
  2. bGroup B (tablet) data after exclusion of one outlying benazepril concentration data point for dog 11 at day 7, 10 h post-dosing. The values that were altered by this redaction are italicised.
  3. AUC, area under the plasma concentration time curve; AUC(0–10), AUC from dosing to 10 h after dosing; AUMC, area under the first moment curve; Cl/F, clearance divided by bioavailability; Cmax, maximum observed concentration; CV, coefficient of variation; MRT, mean residence time; SD, standard deviation.
Group A
Mean645.3230.67.66.714.3980.80.593
Median647.6207.46.35.332.8086.00.540
SD120.379.24.83.143.4839.90.179
CV0.190.340.630.470.790.490.30
Group B (with outlier)
Mean636.1200.39.814.0253.1761.91.528
Median636.5208.27.77.494.7264.70.510
SD35.846.57.116.3120.636.92.411
CV0.060.230.731.162.270.601.58
Group B (without outlier)b
Mean636.1200.39.87.223.8373.80.551
Median636.5208.27.75.583.6079.50.508
SD35.846.57.13.751.6927.00.160
CV0.060.230.730.520.440.370.29

4. In Table 2, ACE should be aligned left.

Ancillary